Guided Therapeutics Reports No Revenue and Increased Losses in Q2 2026

Guided Therapeutics, Inc. reported a challenging financial performance for the second quarter of 2026, with no revenue generated during the period, compared to $117,000 in the same quarter of 2025. The company continues to face significant operational hurdles, including an accumulated deficit of approximately $158.7 million as of June 30, 2026. The net loss attributable to common stockholders for the six months ended June 30, 2026, was $1.6 million, an increase from a loss of $1.3 million in the prior year. The company’s total assets decreased to $1.195 million from $1.324 million at the end of 2025, primarily due to a reduction in cash and cash equivalents.

In terms of operational changes, Guided Therapeutics established a wholly-owned subsidiary, GTHP Turkey, in March 2026, aimed at expanding its market presence. However, the company has not yet achieved regulatory approval for its LuViva device from the U.S. FDA or the China National Medical Products Administration (NMPA), which are critical for its commercial success. The company is currently awaiting a response from the FDA regarding its clinical trial results, which it believes exceed expectations. The lack of regulatory approvals has hindered product sales and revenue generation, leading to a working capital deficit of approximately $5.6 million.

The company’s operational metrics reflect a significant decrease in research and development expenses, which fell to $78,000 in the first half of 2026 from $207,000 in the same period of 2025. This reduction is attributed to the completion of clinical trials necessary for FDA approval. General and administrative expenses also decreased to $878,000 from $924,000, primarily due to lower payroll and benefits costs. However, the company incurred a gain of $222,000 on the remeasurement of a deferred compensation conversion liability, which partially offset its losses.

Guided Therapeutics continues to explore avenues for capital raising to support its operations and regulatory approval processes. The company reported cash flows from financing activities of $885,000 during the first half of 2026, primarily from warrant exercises and the issuance of notes payable. However, the company acknowledges the need for ongoing capital to fund its operations and has indicated that it may need to curtail operations if sufficient funding cannot be secured. The outlook remains uncertain, with the company emphasizing the importance of regulatory approvals and market acceptance for its products to achieve future revenue growth.